The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
Uplizna also hit the target on a number of secondary measures, including: annualised flare rate; flare-free, treatment-free ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The FDA's vaccine advisory panel voted to recommend that this fall’s Covid-19 shots should be updated to target Omicron’s ...
ASCO Annual Meeting kicks off today, showcasing the latest research in cancer therapies to scientists and physicians.
Per AbbVie, the study investigator can offer one of the three SATs — one involving Amgen’s Kyprolis ... cancer drugs ...
Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is a leader in RNAi therapeutics. The ...